Shum Yiu Foon Shum Bik Chuen Memorial Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.
Institute of Precision Medicine and Innovative Drug Discovery (PMID), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.
Int J Mol Sci. 2024 Oct 12;25(20):10991. doi: 10.3390/ijms252010991.
Associations between inflammation and cancer were first discovered approximately 160 years ago by Rudolf Virchow, who observed that tumors were infiltrated with inflammatory cells, and defined inflammation as a pathological condition. Inflammation has now emerged as one of the key mediators in oncogenesis and tumor progression, including pancreatic ductal adenocarcinoma (PDAC). However, the role of inflammatory processes in cancers is complicated and controversial, and the detailed regulatory mechanisms are still unclear. This review elucidates the dynamic interplay between inflammation and immune regulation, microenvironment alteration, metabolic reprogramming, and microbiome risk factors in PDAC, committing to exploring a deeper understanding of the role of crucial inflammatory pathways and molecules for providing insights into therapeutic strategies.
炎症与癌症之间的关联最早是大约 160 年前由鲁道夫·菲尔绍(Rudolf Virchow)发现的,他观察到肿瘤浸润了炎症细胞,并将炎症定义为一种病理状态。现在,炎症已成为致癌和肿瘤进展的关键介质之一,包括胰腺导管腺癌(PDAC)。然而,炎症过程在癌症中的作用是复杂和有争议的,其详细的调节机制尚不清楚。本综述阐述了炎症与免疫调节、微环境改变、代谢重编程以及 PDAC 中微生物组风险因素之间的动态相互作用,致力于更深入地了解关键炎症途径和分子的作用,为治疗策略提供新的思路。